Skip to main content
SpringerLink
Log in

Neue Einteilung der Risikogruppen

Myelodysplastische Syndrome: Was hat sich bei der Therapie getan?

Recent advances in the treatment of myelodysplastic syndromes (MDS)

  • FB_Schwerpunkt-Übersicht
  • Published:
MMW - Fortschritte der Medizin Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1

Author information

Authors and Affiliations

  1. Klinik und Poliklinik für Innere Medizin III, Hämatologie und Onkologie, Klinikum rechts der Isar der TU München, Ismaninger Str. 22, 81675, München, Deutschland

    Marina Lukas

Authors
  1. Marina Lukas
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Marina Lukas.

Ethics declarations

Es liegt kein Interessenkonflikt vor.

Supplementary Information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lukas, M. Myelodysplastische Syndrome: Was hat sich bei der Therapie getan?. MMW - Fortschritte der Medizin 165, 43–45 (2023). https://doi.org/10.1007/s15006-022-2180-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15006-022-2180-5

Keywords:

Search

Navigation